C4 Therapeutics Inc
CCCC1.420USD
-0.020-1.39%
收盤 06/20, 16:00（美東）報價延遲15分鐘
100.81M總市值
虧損本益比TTM
關於 C4 Therapeutics Inc 公司
C4 Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於推進靶向蛋白質降解科學，以創造新一代小分子藥物，改變患者的生活。通過利用其專有的靶向蛋白質降解劑優化器 (TORPEDO) 平臺，設計和優化小分子蛋白質降解劑，這些降解劑可針對其所需靶標，利用人體自然過程破壞不需要的蛋白質。其 TORPEDO 平臺能夠設計兩種類型的蛋白質降解劑，兩種降解劑方法均反映在其臨牀管線中。其候選產品 CFT7455 是一種口服生物可利用的 MonoDAC 降解劑，針對 IKZF1 和 IKZF3 蛋白質靶標，目前正在進行多發性骨髓瘤和非霍奇金淋巴瘤的臨牀開發。其 CFT1946 是一種口服生物可利用的 BiDAC 降解劑，旨在有效且選擇性地對抗 BRAF V600X 突變蛋白。該公司還在開發 CFT8919。
公司簡介
公司代碼CCCC
公司名稱C4 Therapeutics Inc
上市日期Oct 02, 2020
成立日期2015
CEOMr. Andrew J. Hirsch
員工數量110
證券類型Ordinary Share
年結日Oct 02
公司地址490 Arsenal Way
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02472
電話16172310700
網址https://c4therapeutics.com/
公司代碼CCCC
上市日期Oct 02, 2020
成立日期2015
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
165.12K
--
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Ms. Jolie M. Siegel, J.D.
Ms. Jolie M. Siegel, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Courtney Solberg
Ms. Courtney Solberg
Senior Manager - Investor Relations
Senior Manager - Investor Relations
--
--
Dr. Laura Bessen, M.D.
Dr. Laura Bessen, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
165.12K
--
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Wasatch Global Investors Inc
10.52%
Lynx1 Capital Advisors LLC
10.00%
Soleus Capital Management, L.P.
9.83%
OrbiMed Advisors, LLC
9.62%
Betta investment Hong Kong Ltd
6.86%
Other
53.17%
持股股東
持股股東
佔比
Wasatch Global Investors Inc
10.52%
Lynx1 Capital Advisors LLC
10.00%
Soleus Capital Management, L.P.
9.83%
OrbiMed Advisors, LLC
9.62%
Betta investment Hong Kong Ltd
6.86%
Other
53.17%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
27.67%
Investment Advisor
23.95%
Hedge Fund
21.97%
Private Equity
9.62%
Research Firm
7.68%
Corporation
6.86%
Individual Investor
3.25%
Bank and Trust
0.80%
Pension Fund
0.14%
機構持股
更新時間: 3月3日 週一
更新時間: 3月3日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
329
73.88M
107.58%
-3.41M
2024Q4
337
73.17M
103.10%
-6.50M
2024Q3
332
72.91M
103.31%
-3.42M
2024Q2
325
69.49M
100.73%
-3.96M
2024Q1
329
66.54M
97.72%
+3.15M
2023Q4
324
51.20M
103.91%
-2.36M
2023Q3
320
38.85M
79.00%
-14.16M
2023Q2
326
38.30M
78.08%
-12.52M
2023Q1
331
41.73M
85.11%
-15.41M
2022Q4
330
43.22M
88.31%
-12.45M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Wasatch Global Investors Inc
6.07M
8.55%
+395.23K
+6.96%
Dec 31, 2024
Lynx1 Capital Advisors LLC
6.85M
9.65%
-27.78K
-0.40%
Dec 31, 2024
Soleus Capital Management, L.P.
6.98M
9.83%
+374.95K
+5.68%
Dec 31, 2024
OrbiMed Advisors, LLC
4.38M
6.17%
--
--
Dec 31, 2024
Betta investment Hong Kong Ltd
5.57M
7.84%
+5.57M
--
Jan 04, 2024
BlackRock Institutional Trust Company, N.A.
4.88M
6.88%
+606.62K
+14.19%
Dec 31, 2024
The Vanguard Group, Inc.
3.35M
4.71%
-24.71K
-0.73%
Dec 31, 2024
Samlyn Capital, LLC
3.02M
4.25%
+3.02M
--
Dec 31, 2024
Morgan Stanley & Co. LLC
3.27M
4.61%
+1.74M
+114.38%
Dec 31, 2024
BofA Global Research (US)
1.68M
2.36%
-358.59K
-17.61%
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
查看更多
iShares Micro-Cap ETF
佔比0.02%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
Fidelity Enhanced Small Cap ETF
佔比0.01%
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
